Hyperphosphorylated tau is elevated in Alzheimer's disease with psychosis

Journal of Alzheimer's Disease

Volumn 39, Issue 4, 2014, Pages 759-773

  Murray, Patrick S ^a,b   Kirkwood, Caitlin M ^a   Gray, Megan C ^a   Fish, Kenneth N ^a   Ikonomovic, Milos D ^a,b   Hamilton, Ronald L ^a   Kofler, Julia K ^a   Klunk, William E ^a   Lopez, Oscar L ^b   Sweet, Robert A ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; Braak stage; Mini Mental State Examination; psychosis; tau

Indexed keywords

PHOSPHOPROTEIN; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); FEMALE; HUMAN; HUMAN TISSUE; IMAGE PROCESSING; IMMUNOHISTOCHEMISTRY; MALE; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; NEUROLOGIC EXAMINATION; ONSET AGE; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; PSYCHIATRIC DIAGNOSIS; PSYCHOSIS; VERY ELDERLY;

ALZHEIMER'S DISEASE; BRAAK STAGE; MINI-MENTAL STATE EXAMINATION; PSYCHOSIS; TAU;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; COHORT STUDIES; FEMALE; HUMANS; MALE; PHOSPHORYLATION; PSYCHOTIC DISORDERS; TAU PROTEINS;

EID: 84896838538     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-131166     Document Type: Article

References (70)

1. Scarmeas N, Brandt J, Albert M, Hadjigeorgiou G, Papadim-itriou A, Dubois B, Sarazin M, Devanand D, Honig L, Marder K, Bell K, Wegesin D, Blacker D, Stern Y (2005) Delusions and hallucinations are associated with worse outcome in Alzheimer disease. Arch Neurol 62, 1601-1608.
2. Emanuel JE, Lopez OL, Houck PR, Becker JT, Weamer EA, DeMichele-Sweet MA, Kuller L, Sweet RA (2011) Trajectory of cognitive decline as a predictor of psychosis in early Alzheimer disease in the cardiovascular health study. Am J Geriatr Psychiatry 19, 160-168.
3. Sweet RA, Hamilton RL, Lopez OL, Klunk WE, Wisniewski SR, Kaufer DI, Healy MT, DeKosky ST (2000) Psychotic symptoms in Alzheimer's disease are not associated with more severe neuropathologic features. Int Psychogeriatr 12, 547-558.
4. Paulsen JS, Salmon DP, Thal L, Romero R, Weisstein-Jenkins C, Galasko D, Hofstetter CR, Thomas R, Grant I, Jeste DV (2000) Incidence of and risk factors for hallucinations and delusions in patients with probable Alzheimer's disease. Neurology 54, 1965-1971.
5. Farber NB, Rubin EH, Newhouse PA, Kinscherf DA, Miller JP, Morris JC, Olney JW, McKeel DW (2000) Increased neocortical neurofibrillary tangle density in subjects with Alzheimer's disease. Arch Gen Psychiatry 57, 1165-1173.
6. Forstl H, Burns A, Levy R, Cairns N (1994) Neuropatho-logical correlates of psychotic phenomena in confirmed Alzheimer's disease. Br J Psychiatry 165, 53-59.
7. Sweet RA, Nimgaonkar VL, Devlin B, Lopez OL, DeKosky ST (2002) Increased familial risk of the psychotic phenotype of Alzheimer disease. Neurology 58, 907-911.
8. Sweet RA, Bennett DA, Graff-Radford NR, Mayeux R (2010) Assessment and familial aggregation of psychosis in Alzheimer's disease from the National Institute on Aging Late Onset Alzheimer's Disease Family Study. Brain 133, 1155-1162.
9. Bacanu SA, Devlin B, Chowdari KV, DeKosky ST, Nim-gaonkar VL, Sweet RA (2005) Heritability of psychosis in Alzheimer disease. Am J Geriatr Psychiatry 13, 624-627.
10. Geda YE, Schneider LS, Gitlin LN, Miller DS, Smith GS, Bell J, Evans J, Lee M, Porsteinsson A, Lanctot KL, Rosenberg PB, Sultzer DL, Francis PT, Brodaty H, Padala PP, Onyike CU, Ortiz LA, Ancoli-Israel S, Bliwise DL, Martin JL, Vitiello MV, Yaffe K, Zee PC, Herrmann N, Sweet RA, Bal-lard C, Khin NA, Alfaro C, Murray PS, Schultz S, Lyketsos CG (2013) Neuropsychiatric symptoms in Alzheimer's disease: Past progress and anticipation of the future. Alzheimers Dement 9, 602-608.
11. Murray PS, Kumar S, DeMichele-Sweet MA, Sweet RA (2013) Psychosis in Alzheimer's Disease. Biol Psychiatry, doi: 10.1016/j.biopsych.2013.08.020
12. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R (1991) Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol 30, 572-580.
13. DeKosky ST, Scheff SW (1990) Synapse lossin frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity. Ann Neurol 27, 457-464.
14. Scheff SW, Price DA (2006) Alzheimer's disease-related alterations in synaptic density: Neocortex and hippocampus. J Alzheimers Dis 9, 101-115.
15. Mega MS, Lee L, Dinov ID, Mishkin F, Toga AW, Cum-mings JL (2000) Cerebral correlates of psychotic symptoms in Alzheimer's disease. J Neurol Neurosurg Psychiatry 69, 167-171.
16. Staff RT, Shanks MF, Macintosh L, Pestell SJ, Gemmell HG, Venneri A (1999) Delusions in Alzheimer's disease: Spet evidence of right hemispheric dysfunction. Cortex 35, 549-560.
17. Kotrla KJ, Chacko RC, Harper RG, Jhingran S, Doody R (1995) SPECT findings on psychosis in Alzheimer's disease. Am J Psychiatry 152, 1470-1475.
18. Sultzer DL, Mahler ME, Mandelkern MA, Cummings JL, Van Gorp WG, Hinkin CH, Berisford MA (1995) The relationship between psychiatric symptoms and regional cortical metabolism in Alzheimer's disease. J Neuropsychiatry Clin Neurosci 7, 476-484.
19. Koppel J, Sunday S, Goldberg TE, Davies P, Christen E, Greenwald BS (2013) Psychosis in Alzheimer's disease is associated with frontal metabolic impairment and accelerated decline in working memory: Findings from the Alzheimer's Disease Neuroimaging Initiative. Am J Geriatr Psychiatry, doi: 10.1016/j.jagp.2012.10.028
20. Bruen PD, McGeown WJ, Shanks MF, Venneri A (2008) Neuroanatomical correlates of neuropsychiatric symptoms in Alzheimer's disease. Brain 131, 2455-2463.
21. Sweet RA, Panchalingam K, Pettegrew JW, McClure RJ, Hamilton RL, Lopez OL, Kaufer DI, DeKosky ST, Klunk WE (2002) Psychosisin Alzheimer disease:Postmortem magnetic resonance spectroscopy evidence of excess neuronal and membrane phospholipid pathology. Neurobiol Aging 23, 547-553.
22. Murray PS, Kirkwood CM, Gray MC, Ikonomovic MD, Paljug WR, Abrahamson EE, Henteleff RA, Hamilton RL, Kofler JK, Klunk WE, Lopez OL, Penzes P, Sweet RA(2012) beta-Amyloid 42/40 ratio and kalirin expression in Alzheimer disease with psychosis. Neurobiol Aging 33, 2807-2816.
23. Cahill ME, Xie Z, Day M, Photowala H, Barbolina MV, Miller CA, Weiss C, Radulovic J, Sweatt JD, Disterhoft JF, Surmeier DJ, Penzes P (2009) Kalirin regulates cortical spine morphogenesis and disease-related behavioral phenotypes. Proc Natl Acad Sci USA 106, 13058-13063.
24. Selkoe DJ (2002) Alzheimer's disease is a synaptic failure. Science 298, 789-791.
25. Walsh DM, Selkoe DJ (2007) A beta oligomers- A decade of discovery. J Neurochem 101, 1172-1184.
26. Koffie RM, Meyer-Luehmann M, Hashimoto T, Adams KW, Mielke ML, Garcia-Alloza M, Micheva KD, Smith SJ, Kim ML, Lee VM, Hyman BT, Spires-Jones TL(2009) Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci USA 106, 4012-4017.
27. Rapoport M, Dawson HN, Binder LI, Vitek MP, Ferreira A (2002) Tau is essential to beta-amyloid-induced neurotoxic-ity. Proc Natl Acad Sci USA 99, 6364-6369.
28. Shipton OA, Leitz JR, Dworzak J, Acton CE, Tunbridge EM, Denk F, Dawson HN, Vitek MP, Wade-Martins R, Paulsen O, Vargas-Caballero M (2011) Tau protein is required for amyloid beta-induced impairment of hippocampal long-term potentiation. J Neurosci 31, 1688-1692.
29. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, Mucke L (2007) Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 316, 750-754.
30. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82, 239-259.
31. Augustinack JC, Schneider A, Mandelkow EM, Hyman BT (2002) Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol 103, 26-35.
32. deCalignon A, Polydoro M, Suarez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, Pitstick R, Sahara N, Ashe KH, Carlson GA, Spires-Jones TL, Hyman BT (2012) Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 73, 685-697.
33. Liu L, Drouet V, Wu JW, Witter MP, Small SA, Clelland C, Duff K (2012) Trans-synaptic spread of tau pathology in vivo. PLoS One 7, e31302.
34. Mukaetova-Ladinska EB, Harrington CR, Xuereb J, Roth M, Wischik CM (1995) Biochemical, neuropathological, and clinical correlations of neurofibrillary degeneration in Alzheimer's disease. In Treating Alzheimer's and Other Dementias: Clinical Application of Recent Research Advances, Bergener M, Finkel SI, eds. Springer, New York, pp. 57-80.
35. Koppel J, Goldberg TE, Gordon ML, Huey E, Davies P, Keehlisen L, Huet S, Christen E, Greenwald BS (2012) Relationships between behavioral syndromes and cognitive domains in Alzheimer disease: The impact of mood and psychosis. Am J Geriatr Psychiatry 20, 994-1000.
36. Paulsen JS, Ready RE, Stout JC, Salmon DP, Thal LJ, Grant I, Jeste DV (2000) Neurobehaviors and psychotic symptoms in Alzheimer's disease. J Int Neuropsychol Soc 6, 815-820.
37. Sweet RA, Hamilton RL, Healy MT, Wisniewski SR, Hentel-effR, Pollock BG, Lewis DA, DeKosky ST (2001) Alterations of striatal dopamine receptor binding in Alzheimer disease are associated with Lewy body pathology and antemortem psychosis. Arch Neurol 58, 466-472.
38. Tariot PN, Mack JL, Patterson MB, Edland SD, Weiner MF, Fillenbaum G, Blazina L, Teri L, Rubin E, Mortimer JA, Stern Y, Behavioral Pathology Committee of the Consortium to Establish a Registry for Alzheimer's Disease (1995) The behavior rating scale for dementia of the Consortium toEstab-lish a Registry for Alzheimer's Disease. Am J Psychiatry 152, 1349-1357.
39. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brown-lee LM, Vogel FS, Hughes JP, van Belle G, Berg L (1991) The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41, 479-486.
40. Yamamoto T, Hirano A (1986) A comparative study of modified Bielschowsky, Bodian and thioflavin S stains on Alzheimer's neurofibrillary tangles. Neuropathol Appl Neu-robiol 12, 3-9.
41. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen ENH, Ballard C, de Vos RAI, Wilcock GK, Jellinger KA, Perry RH (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology 47, 1113-1124.
42. McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, Dickson D, Dubois B, Duda JE, Feldman H, Gauthier S, Halliday G, Lawlor B, Lippa C, Lopez OL, Carlos MJ, O'Brien J, Playfer J, Reid W (2004) Dementia with Lewy bodies. Lancet Neurol 3, 19-28.
43. Watson RE Jr, Wiegand SJ, Clough RW, Hoffman GE (1986) Use of cryoprotectant to maintain long-term peptide immunoreactivity and tissue morphology. Peptides 7, 155-159.
44. Biernat J, Mandelkow EM, Schroter C, Lichtenberg-Kraag B, Steiner B, Berling B, Meyer H, Mercken M, Vandermeeren A, Goedert M, et al. (1992) The switch of tau protein to an Alzheimer-like state includes the phosphorylation of two serine-proline motifs upstream of the microtubule binding region. EMBO J 11, 1593-1597.
45. Goedert M, Jakes R, Vanmechelen E (1995) Monoclonal antibody AT8 recognises tau proteinphosphorylatedatboth serine 202 and threonine 205. Neurosci Lett 189, 167-169.
46. Moyer CE, Delevich KM, Fish KN, Asafu-Adjei JK, Sampson AR, Dorph-Petersen KA, Lewis DA, Sweet RA (2012) Reduced glutamate decarboxylase 65 protein within primary auditory cortex inhibitory boutons in schizophrenia. Biol Psychiatry 72, 734-743.
47. Fish KN, Sweet RA, Deo AJ, Lewis DA (2008) An automated segmentation methodology for quantifying immunoreactive puncta number and fluorescence intensity in tissue sections. Brain Res 1240, 62-72.
48. Howard CV Reed MG (1998) Estimation of component volume and volume fraction. In Unbiased Stereology: Three Dimensional Measurement in Microscopy, Howard CV, Reed MG, eds. BIOS Scientific Publishers, Oxford, UK, pp. 55-65.
49. Kuperstein I, Broersen K, Benilova I, Rozenski J, Jonckheere W, Debulpaep M, Vandersteen A, Segers-Nolten I, Van Der WK, Subramaniam V, Braeken D, Callewaert G, Bartic C, D'Hooge R, Martins IC, Rousseau F, Schymkowitz J, De SB (2010) Neurotoxicity of Alzheimer's disease Abeta peptides is induced by small changes in the Abeta42 to Abeta40 ratio. EMBO J 29, 3408-3420.
50. Zempel H, Thies E, Mandelkow E, Mandelkow EM (2010) Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous tau into dendrites, tau phosphorylation, and destruction of microtubules and spines. J Neurosci 30, 11938-11950.
51. Hollingworth P, Sweet R, Sims R, Harold D, Russo G, Abraham R, Stretton A, Jones N, Gerrish A, Chapman J, Ivanov D, Moskvina V, Lovestone S, Priotsi P, Lupton M, Brayne C, Gill M, Lawlor B, Lynch A, Craig D, McGuinnessB, Johnston J, Holmes C, Livingston G, Bass NJ, Gurling H, McQuillin A, Holmans P, Jones L, Devlin B, Klei L, Barmada MM, Demirci FY, DeKosky ST, Lopez OL, Passmore P, Owen MJ, O'Donovan MC, Mayeux R, Kamboh MI, Williams J (2012) Genome-wide association study of Alzheimer's disease with psychotic symptoms. Mol Psychiatry 17, 1316-1327.
52. Kojima Y, Miyoshi H, Clevers HC, Oshima M, Aoki M, Taketo MM (2007) Suppression of tubulin polymerization by the LKB1-microtubule-associated protein/microtubule affinity-regulating kinase signaling. J Biol Chem 282, 23532-23540.
53. Wang JW, Imai Y, Lu B (2007) Activation of PAR-1kinase and stimulation of tau phosphorylation by diverse signals require the tumor suppressor protein LKB1. J Neurosci 27, 574-581.
54. Larson M, Sherman MA, Amar F, Nuvolone M, Schneider JA, Bennett DA, Aguzzi A, Lesne SE (2012) The complex PrP(c)-Fyn couples human oligomeric Abeta with pathological tau changes in Alzheimer's disease. J Neurosci 32, 16857-16871a.
55. Schneider A, Biernat J, von BM, Mandelkow E, Mandelkow EM (1999) Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry 38, 3549-3558.
56. Cash AD, Aliev G, Siedlak SL, Nunomura A, Fujioka H, Zhu X, Raina AK, Vinters HV, Tabaton M, Johnson AB, Paula-Barbosa M, Avila J, Jones PK, Castellani RJ, Smith MA, Perry G (2003) Microtubule reduction in Alzheimer's disease and aging is independent of tau filament formation. Am J Pathol 162, 1623-1627.
57. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del TK (2006) Staging of Alzheimer disease-associated neurofibrillarypathology using paraffin sections andimmuno-cytochemistry. Acta Neuropathol 112, 389-404.
58. Nelson PT, Braak H, Markesbery WR (2009) Neuropathology and cognitive impairment in Alzheimer disease: A complex but coherent relationship. J Neuropathol Exp Neurol 68, 1-14.
59. Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Trojanowski JQ, Vinters HV, Hyman BT (2012) National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: A practical approach. Acta Neuropathol 123, 1-11.
60. Hyman BT, Trojanowski JQ (1997) Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol 56, 1095-1097.
61. Nelson PT, Jicha GA, Schmitt FA, Liu H, Davis DG, Mendiondo MS, Abner EL, Markesbery WR (2007) Clini-copathologic correlations in a large Alzheimer disease center autopsy cohort: Neuritic plaques and neurofibrillary tangles "do count" when staging disease severity. J Neuropathol Exp Neurol 66, 1136-1146.
62. Crum RM, Anthony JC, Bassett SS, Folstein MF (1993) Population-based norms for the Mini-Mental State Examination by age and educational level. JAMA 269, 2386-2391.
63. Teri L, McCurry SM, Edland SD, Kukull WA, Larson EB (1995) Cognitive decline in Alzheimer's disease: A longitudinal investigation of risk factors for accelerated decline. J Gerontol A Biol Sci Med Sci 50A, M49-M55.
64. Gartner U, Janke C, Holzer M, Vanmechelen E, Arendt T (1998) Postmortem changes in the phosphorylation state of tau-protein in the rat brain. Neurobiol Aging 19, 535-543.
65. Glynn MW, McAllister AK (2006) Immunocytochemistry and quantification of protein colocalization in cultured neurons. Nat Protoc 1, 1287-1296.
66. Sugiyama Y, Kawabata I, Sobue K, Okabe S (2005) Determination of absolute protein numbers in single synapses by a GFP-based calibration technique. Nat Methods 2, 677-684.
67. Bobinski M, Wegiel J, Tarnawski M, de Leon MJ, Reisberg B, Miller DC, Wisniewski HM (1998) Duration of neurofibrillary changes in the hippocampal pyramidal neurons. Brain Res 799, 156-158.
68. Schindowski K, Bretteville A, Leroy K, Begard S, Brion JP, Hamdane M, Buee L(2006) Alzheimer's disease-like tau neu-ropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am J Pathol 169, 599-616.
69. Braak E, Braak H, Mandelkow EM (1994) A sequence of cytoskeleton changes related to the formation of neurofibrillarytangles and neuropil threads.Acta Neuropathol 87, 554-567.
70. Braak H, Braak E (1996) Evolution of the neuropathology of Alzheimer's disease. Acta Neurol Scand Suppl 165, 3-12.